Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17522199 | 0.89 | PIK3CD (0.43) | PIK3CDEPHX2EPHX1MEN1ALDH1A1 | |
| SCHEMBL17522201 | 0.89 | PIK3CD (0.43) | PIK3CDEPHX2EPHX1MEN1ALDH1A1 | |
| SCHEMBL17522138 | 0.89 | PIK3CD (0.43) | PIK3CDEPHX2EPHX1MEN1ALDH1A1 | |
| SCHEMBL29291140 | 0.86 | HRH3 (0.45) | MEN1ALDH1A1KMT2AKCNH2HRH3 | |
| SCHEMBL26361839 | 0.85 | PIK3CD (0.43) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL27793398 | 0.84 | ALDH1A1 (0.40) | MEN1ALDH1A1KMT2AKCNH2HRH3 | |
| SCHEMBL11310199 | 0.83 | PIK3CD (0.42) | PIK3CDEPHX2EPHX1MEN1KMT2A | |
| SCHEMBL15730412 | 0.82 | MEN1 (0.47) | EPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL13065450 | 0.81 | PIK3CD (0.47) | PIK3CDEPHX2EPHX1MEN1KMT2A | |
| SCHEMBL25075234 | 0.81 | ALDH1A1 (0.50) | MEN1ALDH1A1KMT2AKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771677-B2 | Immunomodulating urea azalides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-20210179595-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-06-17 | — | — | US | disclosed |
| US-10959984-B2 | Methods for treating cancer with RORγ inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
| US-20090075968-A1 | CETP inhibitors | SAKAKI JUNICHI | 2009-03-19 | — | — | US | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179595-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | PIK3CD 4028/4885EPHX2 2463/4885EPHX1 2434/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | PIK3CD 1237/4885EPHX2 4282/4885EPHX1 4497/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PIK3CD 2764/4885EPHX2 773/4885EPHX1 1797/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | PIK3CD 1817/4885EPHX2 4118/4885EPHX1 4412/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | PIK3CD 252/4885EPHX2 3639/4885EPHX1 2632/4885 |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | PIK3CD 4028/4885EPHX2 2463/4885EPHX1 2434/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PIK3CD 2764/4885EPHX2 773/4885EPHX1 1797/4885 |
| US-11771677-B2 | Immunomodulating urea azalides | ARG1, IL2, CD209 | PIK3CD 1775/4885EPHX2 2958/4885EPHX1 2383/4885 |
| US-10959984-B2 | Methods for treating cancer with RORγ inhibitors | RORB, RORC, RORA | PIK3CD 2448/4885EPHX2 1277/4885EPHX1 1367/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | PIK3CD 2764/4885EPHX2 773/4885EPHX1 1797/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | PIK3CD 559/4885EPHX2 3632/4885EPHX1 2236/4885 |
| US-20090075968-A1 | CETP inhibitors | CETP, PCSK9, MTTP | PIK3CD 2168/4885EPHX2 1474/4885EPHX1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.